All AbMole products are for research use only, cannot be used for human consumption.
Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral compound for Visceral leishmaniasis, effective against both promastigotes and amastigotes.
J Biochem Mol Toxicol. 2025 Jun 01;39(6):e70309.
Design, Synthesis, and Evaluation of Novel Quinazolin‐4(3H)‐One Derivatives: Anti‐Leishmanial Activity, Selectivity, and Molecular Docking Insights
Miltefosine purchased from AbMole
| Molecular Weight | 407.57 |
| Formula | C21H46NO4P |
| CAS Number | 58066-85-6 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Jaime A Soto, et al. Miltefosine Treatment of Cutaneous Leishmaniasis
[4] Paulo R L Machado, et al. Miltefosine and cutaneous leishmaniasis
| Related Akt Products |
|---|
| AT7867
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase with an IC50 of 17 nM. |
| GSK690693
GSK690693 is a potent Akt inhibitor (Akt1 IC50 = 2 nM, Akt2 IC50 = 13 nM, Akt3 IC50 = 9 nM) which also inhibited the phosphorylation of the downstream target GSK3b in cells. |
| Perifosine
Perifosine is an orally active Akt inhibitor, the antiproliferative properties of Perifosine with an IC50 of 0.6–8.9 µM. |
| MK-2206 2HCl
MK-2206 is a novel allosteric inhibitor of Akt with IC50 values of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. |
| Ipatasertib
Ipatasertib (GDC-0068, RG7440) is a potent and selective, ATP-competitive Akt inhibitor with IC50 values of 5 to 18 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
